Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Accounts Payables: 2016-2020

Historic Accounts Payables for Monopar Therapeutics (MNPR) over the last 3 years, with Sep 2020 value amounting to $542,068.

  • Monopar Therapeutics' Accounts Payables rose 12.07% to $542,068 in Q3 2020 from the same period last year, while for Sep 2020 it was $542,068, marking a year-over-year increase of 12.07%. This contributed to the annual value of $403,967 for FY2021, which is 9.75% down from last year.
  • Per Monopar Therapeutics' latest filing, its Accounts Payables stood at $542,068 for Q3 2020, which was up 3.10% from $525,748 recorded in Q2 2020.
  • Monopar Therapeutics' 5-year Accounts Payables high stood at $724,165 for Q4 2019, and its period low was $64,510 during Q4 2016.
  • Moreover, its 3-year median value for Accounts Payables was $468,272 (2019), whereas its average is $462,957.
  • In the last 5 years, Monopar Therapeutics' Accounts Payables skyrocketed by 383.44% in 2017 and then dropped by 23.53% in 2020.
  • Quarterly analysis of 5 years shows Monopar Therapeutics' Accounts Payables stood at $64,510 in 2016, then surged by 383.44% to $311,867 in 2017, then climbed by 28.12% to $399,551 in 2018, then surged by 81.24% to $724,165 in 2019, then grew by 12.07% to $542,068 in 2020.
  • Its Accounts Payables was $542,068 in Q3 2020, compared to $525,748 in Q2 2020 and $443,520 in Q1 2020.